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Abstract
Purpose Angiogenesis plays an important role in the growth and metastatic spread of solid tumours and is characterised by the
expression of integrins on the cell surface of endothelial cells. Radiolabelled RGD peptides specifically target angiogenesis-related
αvβ3 integrins, expressed on the activated endothelial cells of sprouting blood vessels. Here, we validated the feasibility of
68Ga[Ga]-
DOTA-E-[c(RGDfK)]2 (
68Ga-RGD) PET/CT to visualise angiogenesis in patients with oral squamous cell carcinoma (OSCC).
Methods Ten patients with OSCC and scheduled for surgical resection including elective neck dissection received an intrave-
nously administration of 68Ga-RGD (42 ± 8 μg; 214 ± 9 MBq). All patients subsequently underwent dynamic (n = 5) or static
PET/CT imaging (n = 5) for 60min or for 4 min/bed position at 30, 60 and 90min after injection, respectively. Quantitative tracer
uptake in tumour lesions was expressed as standardised uptake values (SUV). Additionally, tumour tissue was
immunohistochemically stained for αvβ3 integrin to assess the expression pattern.
Results 68Ga-RGD tumour accumulation was observed in all patients. At 60 min post injection, tumour SUVmax ranged between
4.0 and 12.7. Tracer accumulation in tumour tissue plateaued at 10 min after injection. Uptake in background tissue did not
change over time, resulting in tumour-to-muscle tissue of 6.4 ± 0.7 at 60 min post injection.
Conclusions 68Ga-RGD PET/CT of αvβ3 integrin expression in OSCC patients is feasible with adequate tumour-to-background
ratios. It will provide more insight in angiogenesis as a hallmark of the head and neck squamous cell carcinomas’ tumour
microenvironment.
Trial registration https://eudract.ema.europa.eu no. 2015-000917-31
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Introduction
Head and neck squamous cell carcinomas of the mucosal sur-
faces (HNSCC) are the most common type of all head and
neck cancers, with approximately 890,000 new cases in 2018
worldwide [1]. Current treatment options for HNSCC depend
on the primary site of the cancer, stage, resectability, and wish
to preserve functional outcome [2, 3]. In oral squamous cell
carcinomas (OSCC), surgery with on indication followed by
(chemo)radiotherapy is the first choice of treatment, whereas
in most other sites in the head and neck region,
(chemo)radiation is the first choice. Furthermore, for locally
advanced and recurrent diseases, several advances to treat
them with molecular targeted therapies have been made [4].
Despite these advances, treatment is often not effective in
many patients, while still causing significant toxicity. This
illustrates the importance of identifying predictive biomarkers
to stratify patients who are most likely to benefit from
(molecular) targeted therapies. A better understanding of the
tumour microenvironment and its effect on treatment resis-
tance could further improve the management of HNSCC.
Angiogenesis, the formation of new blood vessels, is a
hallmark of tumour progression and metastatic spread [5, 6].
Its role in HNSCC has been studied intensively, and various
strategies inhibiting the cross talk between signalling path-
ways involved in the growth and metastasis of HNSCC have
been revealed as potential therapeutic target [7, 8].
Integrins play a key factor in controlling cell-cell signalling
during angiogenesis and may serve as an angiogenesis-related
biomarker [5]. The most extensively studied integrin, αvβ3, is
expressed on activated endothelial cells during normal tissue
regeneration and becomes aberrantly expressed in cancers,
subsequently leading to tumour progression and metastatic
spread [9]. Whereas αvβ3 integrins can be expressed on both
tumour cells and tumour-associated neovasculature, it is a
selective target of neovasculature in HNSCC [10]. Thus, it
may provide important information on tumour microvascula-
ture in HNSCC. Using positron emission tomography/
computed tomography (PET/CT), radiolabelled peptides
targeting the αvβ3 integrins enable the noninvasive and early
evaluation of microenvironmental changes associated with
treatment success or failure and may provide a better under-
standing of angiogenesis-related tumour characteristics.
Integrinαvβ3 can be targeted by radiotracers containing the
arginine-glycine-aspartic acid (RGD) amino acid sequence
present in extracellular matrix proteins such as vitronectin
[11]. In recent years, many studies focused on the potential
of molecular imaging with RGD-containing peptides targeting
αvβ3 integrins [12]. Several monomeric and multimeric
68Ga-
labelled RGD compounds have been developed and were
studied in glioblastoma [13], cervical and ovarian cancer
[14] and lung adenocarcinoma [15]. The dimeric radiotracer
[68Ga]Ga-DOTA-E-[c(RGDfK)]2 (
68Ga-RGD) has
preclinically shown its potential for imaging of angiogenesis
in HNSCC [16, 17], but only limited data from clinical studies
is available. Therefore, we aim to study the safety,
biodistribution and kinetics of 68Ga-RGD and characterise
αvβ3 integrin expression patterns in patients prior to primary
surgical resection of an OSCC.
Patients and methods
Patients
This prospective study was approved by the regional ethics
review board (region Arnhem-Nijmegen) under protocol
number CMO2015-1813. The study (EudraCT 2015-
000917-31) is registered in Dutch trial register no.
NL52649.091.15. Written informed consent was obtained
from all participants included in this study. All procedures
performed in this study were in accordance with the ethical
standards of the institutional and national research committee
and with the 1964 Helsinki declaration.
Twelve patients with proven squamous cell carcinoma of
the oral cavity were originally included, of which 10 patients
completed the study protocol. All patients were scheduled for
surgical resection. Patients were eligible when diagnosed with
a tumour diameter of at least 1.5 cm, classified according to
radiologic criteria obtained from either MRI or CT within
4 weeks prior to the screening visit. Patients with contra-
indications for PET/CT, and/or an impaired renal or liver func-
tion (estimated glomerular filtration rate by the modification
of diet in renal disease formula (eGFR (MDRD)) ≤ 60ml/min,
aspartate aminotransferase and alanine aminotransferase
levels ≥ 3x upper limit of normal, or total bilirubin ≥ 2x upper
limit of normal), or when diagnosed with other serious ill-
nesses, were not eligible. 68Ga-RGD PET/CT was scheduled
2–7 days prior to the planned surgical intervention. A study
flowchart of the design of the study is provided in Fig. 1.
68Ga-RGD synthesis
DOTA-E-[c(RGDfK)]2 was synthesised by coupling
E-[c(RGDfK)]2 (Peptides International, Louisville, KY,
USA) and DOTA(tris)Bu (1,4,7,10-Tetraazacyclododecane-
1,4,7,10-tetraacetic acid) (Macrocyclics, Dallas, TX, USA),
as described previously [17–19]. Synthesis complied with
good manufacturing practice (GMP) regulations for human
use. Radiolabelling of DOTA-E-[c(RGDfK)]2 was performed
on a Scintomics GRP module (Scintomics GmbH,
Fürstenfeldbruck, Germany) connected to one or two GMP-
grade 68Ge/68Ga generators (IGG101 GalliaPharm, Eckert
and Ziegler, Berlin, Germany). A Scintomics reagent and
hardware kit for synthesis of 68Ga-peptides using cationic pu-
rification (SC-01, ABX, Radeberg, Germany) was used for
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elution of the 68Ge/68Ga generator, radiolabelling and purifi-
cation of [68Ga]Ga-DOTA-E-[c(RGDfK)]2 (
68Ga-RGD).
After radiosynthesis, quality control of 68Ga-RGD was per-
formed according to the European Pharmacopoeia (Ph Eur)
standards including verification of radiochemical purity and
colloid content using reverse-phase high-performance liquid
chromatography and instant thin-layer chromatography, pH
determination using a pH indicator strip, assessment of endo-
toxin content using Endosafe equipment (Charles River,
Leiden, The Netherlands) and testing of sterility. All injected
preparations met the quality control criteria and had a radio-
chemical purity > 99%.
68Ga-RGD PET/CT imaging
Included patients had no restrictions in food or medication
intake. 68Ga-RGD was administered intravenously using a
slow bolus injection of 8 ml over 40 s (200 ± 29 MBq; range
119–218 MBq, 42 ± 8 μg; range 34–58 μg). The net injected
dose was calculated by measuring the syringe before and after
68Ga-RGD administration using a dedicated dose calibrator
(VDS-405, Comecer, Joure, The Netherlands). Patients were
monitored for (severe) adverse events according to the
Common Terminology Criteria for Adverse Events, version
4.03. Venous blood samples at 1, 2, 5, 10, 30 and 90 min after
injection were taken for pharmacokinetic and safety analysis.
The concentration of 68Ga-RGD in the blood samples (Bq/ml)
was calculated by gamma counter (Wizard Detector Gamma
Counter, PerkinElmer Inc., Waltham, MA, USA) while simul-
taneously measuring 1% standards. Safety analysis included a
complete blood count test and assessment of kidney and liver
function by measuring the eGFR (MDRD), total bilirubin and
aspartate aminotransferase and alanine aminotransferase
levels.
Five patients underwent three static whole-body PET/CTat
30, 60 and 90 min post injection on a Biograph 40 mCT
scanner (Siemens Medical Solutions, Knoxville TN, USA)
equipped with a dual-slice CT for 4 min of PET data per bed
position, with bed positions from the base of the skull to tro-
chanter major. For each PET/CT image, two image recon-
structions were used, with a TrueX algorithm with point
spread function (PSF) and time of flight (TOF) measurements,
using three iterations, 21 subsets, matrix size 256 × 256 (pixel
spacing of 3.2 mm) or 200 × 200 (pixel spacing of 4.07 mm),
full width at half maximum (FWHM) of 5 mm. Post-
processing was performed using a 3D Gaussian filter kernel,
7.5 or 3 mm. The other five patients underwent 60 min dy-
namic 68Ga-RGD PET/CT starting at start of injection, of the
head and neck region (15 cm FOV), to obtain time–activity
curves in malignant lesions. These images were reconstructed
in 33 frames (1 × 40 s, 10 × 5 s, 3 × 10 s, 2 × 15 s, 5 × 30 s, 5 ×
120 s, 5 × 300 s and 2 × 600 s). For all patients, a low-dose CT
scan was acquired for attenuation correction and anatomical
reference, with an automatically modulated X-ray tube volt-
age and current (100 kV, 30 mA) using Care kV and Care
Dose4D (Siemens Healthcare), 512 × 512 voxels; 0.98 pixel
Fig. 1 Flowchart of the
characteristics of the study design
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spacing; 3 mm slice thickness; 1 pitch. The CT images for
anatomical reference were reconstructed with a B31f convo-
lution kernel, slice thickness 5 mm.
Tissue and staining
Representative material from tumour and the lymph nodes
from the resection specimen of all patients was selected by
the pathologist (ACHEG). Four-μm sections, derived from
formalin-fixed, paraffin-embedded tissue, were used for stain-
ing. Sections were mounted on Superfrost slides (New Silane
III, Mutopure Chemicals Co. Ltd., Tokyo, Japan) and subse-
quently stained for integrin αvβ3 (anti-αvβ3 integrin mono-
clonal antibody; AB7166, clone BV3, 1:50, Abcam,
Cambridge, UK), and for Ki-67 and CD34 using a double
staining protocol. A detailed description of the staining proto-
cols can be found in Online Resource 1.
Image analysis
PET data
All 68Ga-RGD PET/CT scans were evaluated by two experi-
enced nuclear medicine physicians (WJGO, EHJGA) on a
dedicated workstation (Oasis software, Segami Corporation,
Columbia, MD, USA) with a PET/CT viewer for automatic
image registration. A volume-of-interest (VOI) around the tu-
mour mass was manually drawn to obtain a maximum
standardised uptake value (SUVmax) of the tumour area—
drawn on the static PET/CT image acquired 60 min post
injection—and to determine the 41% SUVmax isocontour
and SUVpeak (highest mean SUV value of 1 cm
3) within this
tumour volume [20]. The same analysis was applied on the
dynamic imaging series, in which a reconstructed frame of
4 min (56–60 min p.i.) was extracted from the dynamic imag-
ing series to obtain a static image for tumour volume delinea-
tion. The dynamic imaging series were also used to obtain
time–activity curves using the PMOD Medical Imaging
Program version 3.15 (PMOD technologies LLC, Zürich,
Switzerland). Curves were estimated for both tumour lesions
and background tissue. Tumour delineation was based on the
evaluation in Oasis (Oasis software, Segami Corporation,
Columbia, MD, USA), drawn on the last frame of the PET
series, and subsequently copied to the other frames. For time–
activity curves of the muscle, a VOI of 1.5 ml was defined in
dorsolateral musculature (contralateral to the tumour) using
the CT images and subsequently copied to the dynamic
dataset. For the time–activity curves of the tracer distribution
in the parotid gland and blood pool, VOIs were defined on the
CT images within the contralateral parotid gland, carotid ar-
tery and jugular vein and subsequently projected on the dy-
namic PET dataset.
Immunohistological analysis
Histological evaluation (HE) and αvβ3 integrin expression
pattern were qualitative analysed using light microscopy
(Leica DMC2900, Leica Microsystems, Heerbrugg,
Switzerland). Besides, an Axio Scope.A1 microscope (Zeiss,
Carl Zeiss Bv, The Netherlands) directed by iVision software
was used to scan for three signals: DAPI (all nuclei), Alexa-
568 (Ki-67) and Alexa-647 (CD34) by means of a 10× objec-
tive using standardised shutter times for each signal (5, 500
and 250 ms, respectively). After scanning, grey-scale images
of all three recorded signals were used for analysis.
Thresholds for segmentation of the fluorescent signals were
interactively set above the background staining for each indi-
vidual marker and adjusted for each sample in order to opti-
mise the signal to background ratio using Fiji (ImageJ, Wayne
Rasband, National Institute of Mental Health, National
Institutes of Health). The resulting binary images were used
to calculate the fraction of Ki-67 relative to the total tumour
area (Ki-67 labelling index), and the microvessel density
(MVD) as number of vascular structures per mm2 using the
CD34 staining. To minimise bias of nonspecific staining, only
positive signals exceeding 5 pixels (vessels) and 2 pixels
(nuclei) were included.
Statistical analysis
Numerical data are presented as mean ± standard deviation
(SD). Patient-based, lesion-based and tissue-based analyses
were performed. The biological half-life of 68Ga-RGD was
calculated using bi-exponential regression analysis in
MATLAB version R2014b (MathWorks, Natick, MA,
USA). The analyses of optimal imaging time point and uptake
values were analysed using SPSS Statistics, version 22.0.0.1
(IBM), with a one-way ANOVA followed by a Bonferroni
post hoc test to adjust for multiple comparisons. The correla-
tion between 68Ga-RGD uptake, Ki-67 labelling index and
MVD was evaluated by linear regression analysis using
Graphpad Prism (version 5.03 GraphPad Software), and the
Pearson’s correlation coefficient was calculated. In all cases,
the level of significance was set to P < 0.05.
Results
Patient demographics
Ten patients with an OSCC completed all study procedures.
Patient characteristics, clinical and pathological tumour clas-
sification (TNM classification, 8th edition of the American
Joint Committee on Cancer), histology and basic imaging
findings of these patients are summarised in Table 1. Five
patients underwent whole body 68Ga-RGD PET/CT at 30,
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60 and 90 min post injection. Four patients underwent 60-min
dynamic 68Ga-RGD PET/CT, and one patient for 30 min. One
patient did not receive 68Ga-RGD injection, due to a failed
production. One patient experienced severe claustrophobia
during scanning, which was considered an adverse event un-
related to 68Ga-RGD injection. 68Ga-RGD PET/CT was
discontinued; no available dataset for analysis was available.
Safety analysis
All patients were monitored for 2 hours after radiotracer in-
jection and no changes in vital signs nor any (serious) adverse
events were observed (data on file). Furthermore, all labora-
tory values were within normal ranges (data on file).
Whole blood and plasma concentrations of 68Ga-RGD
68Ga-RGD rapidly cleared from the blood. The mean levels in
whole blood were 27.5 ± 19 kBq/ml, 9.8 ± 6.9 kBq/ml, 6.5 ±
5.0 kBq/ml and 4.7 ± 3.5 kBq/ml, at 5, 30, 60 and 90 min post
injection, respectively. The mean concentration of 68Ga-RGD
in whole blood differed from the mean concentration of 68Ga-
RGD in plasma (Online Resource 2) indicating that the 68Ga-
RGD is not taken up by the blood cells. When fitting a bi-
exponential curve to the PET/CT data (using all time frames),
a distribution half-life (t1/2α) of 0.14 ± 0.07 min and 0.70 ±
0.53 min, and an elimination half-life phase (t1/2β) of 17.7 ±
8.19 min and 18.6 ± 7.42 min, for arterial blood and venous
blood, respectively, were found. No significant difference in
the elimination half-life was found between calculation based
on blood samples’measurements (23.0 ± 2.3 min) or based on
data derived from PET/CT (t(3) = 0.664, P = 0.55).
Quantitative analysis of 68Ga-RGD in tumour
and biodistribution in normal tissue
The mean SUVmax in tumour tissue at 30, 60 and 90 min post
injection was 5.7 ± 0.8, 5.5 ± 1.2 and 4.8 ± 1.2 (n = 5). These
uptake differences between the three imaging time points were
not statistically significant (F(2,12) = 0.889, P = 0.44). All dy-
namic PET images showed a slight increase in tracer uptake in
tumour tissue during 10 min, followed by a plateau phase up
to 60 min post injection. In one patient, the tumour tissue
demonstrated a slower increase in tracer accumulation and
reached a pla teau phase 15 min af te r in jec t ion
(Online Resource 3). This tumour showed a distinct morphol-
ogy on MRI imaging (patient 6) as compared with the other
patients, with a severe inflammatory process surrounding the
tumour tissue. Muscle tissue activity in the dorsolateral mus-
cles and background parotid gland activity showed no marked
changes in radiotracer uptake over time (Fig. 2 and
Online Resource 4). Tumour-muscle tissue ratios were higher
than 4.0 for every time point from 10 min after injection and
increased up to more than 6.0 at the last time point (mean ratio
6.4 ± 0.7). The kidney, liver and bladder showed the highest
accumulation of 68Ga-RGD in normal tissue and organs
(Online Resource 5).
Table. 1 Patient characteristics within this study cohort










Tumour characterisation (with negative growth
characteristics)
1 69 M cT4aN0M0 Whole
body
static
6.5 pT4aN2bM0 13 Moderately differentiated SCC (discohesive growth
pattern and perineural growth)
2 74 M cT4aN0M0 Whole
body
static
7 pT4aN1M0 20 Moderately differentiated SCC
3 71 F cT3N0M0 Whole
body
static
5.5 pT4aN0M0 9 Well-differentiated SCC
4 65 M cT4aN0M0 Whole
body
static
4.7 pT1N0M0 8 Moderately differentiated SCC
(discohesive growth pattern)
5 63 M cT3N0M0 Dynamic 4 pT2N0M0 8 Moderately differentiated SCC
6 80 F cT4aN1M0 Dynamic* 8.4 pT4aN3bM0 25 Moderately differentiated SCC (discohesive growth
pattern)
7 55 M cT3N1M0 Dynamic 12.7 pT3N1M0 7 Moderately differentiated SCC (perineural growth)
8 37 F cT3N0M0 Dynamic 9.7 pT2N3bM0 19 Moderately differentiated SCC
9 70 M cT3N0M0 Dynamic 6.8 pT2N1M0 20 Moderately differentiated SCC
10 63 M cT3N0M0 Dynamic 9.4 pT4aN2bM0 20 Moderately differentiated SCC (discohesive growth
pattern and perineural growth)
*Patient that only underwent 30-min dynamic scanning
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Immunohistological analysis of αvβ3 integrin
expression
Thirty-one cell blocks (primary tumours and lymph node me-
tastasis) of the 10 patients were available. A distinct pattern of
staining was observed, with integrin αvβ3 predominantly
expressed in endothelial cells of tumour-associated blood ves-
sels. As shown in Fig. 3, a heterogeneous distribution of both
αvβ3 integrin positive and negative blood vessels was ob-
served. Most positive vessels were observed at the invasive
front, of the tumour, but quantitative analysis of this observa-
tion was not feasible. In two patients with a squamous cell
carcinoma with many keratinization, a strong staining of the
tumour cells was observed, whereas other tumours showed no
staining of the tumour cells. Furthermore, integrin αvβ3 im-
munohistochemical staining was to a lesser extent observed in
the cytoplasm of tumour and soft tissue. Red blood cells
showed nonspecific staining in some samples. The MVD of
the primary tumour samples ranged from 155 to 352 mm−2
(mean 246 mm−2) and the Ki-67 labelling index from 0.1 to
0.9 (mean 0.5). There was no correlation betweenMVDorKi-
67 labelling index and SUV41% values (R = 0.20; P = 0.57 and
R = 0.16; P = 0.67, respectively), possibly due to the limited
number of study subjects.
Characterisation of tumour tissue and lymph node
metastasis by 68Ga-RGD PET
All primary tumours could be identified by 68Ga-RGD PET/
CT (a representative image is provided in Fig. 4). The mean
tumour volume as determined by 68Ga-RGD PET/CT was
13.7 ± 5.6 ml. A weak correlation between tumour volume
and tumour SUVmax was observed (R = 0.69, P = 0.041), pos-
sibly due to partial volume effect.
A total of 321 lymph nodes were dissected of which 13
lymph nodes showed metastasis. We observed radiotracer up-
take in six lymph nodes in five patients (mean SUVmax 4.4 ±
2.3 (range 1.8–7.6)). The elective neck dissection revealed
metastatic disease in 67% (4/6) of the RGD positive lymph
nodes. The two lymph nodes with 68Ga-RGD accumulation
but without confirmed metastatic disease were not suspicious
on dynamic contrast-enhanced MRI or CT images. The elec-
tive neck dissection revealed an additional nine small lymph
node metastases, which remained undetected during preoper-
ative diagnostic imaging, including 68Ga-RGD PET/CT. The
smallest lymph node metastasis that was detected with 68Ga-
RGD PET/CT had a diameter of 6 mm.
Discussion
In this study, we investigated the in vivo biodistribution and
kinetics of 68Ga-RGD in patients with primary squamous cell
carcinomas of the oral cavity prior to resection and correlated
these findings with histopathology. The purpose was to eval-
uate neoangiogenesis in OSCC, rather than the utility of 68Ga-
RGD PET/CT for staging purposes. The 68Ga-RGD PET/CT
images revealed variable targeting in all primary tumours.
Immunohistological analysis confirmed αvβ3 integrin expres-
sion within the HNSCC.
Because data on the in vivo biodistribution and kinetics of
the dimeric 68Ga-RGD in patients is limited [15, 21] and non-
existent for HNSCC, we investigated detailed tissue distribu-
tion kinetics in this study. A fast blood clearance was observed
using the PET/CT images as image-derived input function,
with a venous distribution half-life of 0.14 ± 0.07 min and an
elimination half-life phase of 18.6 ± 7.42 min. These results
are in line with reported clinical studies on similar
radiolabelled RGD peptides in other cancer patients [22], but
limited venous blood samples at early time points prevented
accurate assessment and validation of the biological clearance
rate of 68Ga-RGD.
Initial preclinical observations with 68Ga-labelled dimeric
RGD demonstrated favourable radiochemical characteristics,
showing adequate tumour-to-normal tissue ratios and imaging
characteristics as compared with monomeric [17, 19] or
Fig. 2 Mean time–activity curves
of 68Ga-RGD over 60 min after
injection in tumour, blood pool,
parotid tissue and muscle tissue of
patients 6–10. Values are
expressed as mean of five patients
until 30 min and mean of four
patients after 30 min, since one
patient prematurely ended dy-
namic scanning (at 30 min). Data
are presented as cumulative data
at the end of each frame
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trimeric RGD compounds [16]. HNSCC lesions were detected
with sufficient tumour-to-background ratios and absolute
standardised tumour SUVmax ranged from 4.7 to 12.7. These
findings indicate that higher uptake values can be achieved as
compared with, for example, the monomeric 18F-Galacto-
RGD compound, which showed a mean SUVmax of 3.4 ±
1.2 in HNSCC [23]. αvβ3 integrin-mediated uptake in normal
tissue was seen in the kidneys, bladder, liver, spleen and in-
testines [17]. Moreover, uptake in the salivary glands, choroid
plexus and thyroid tissue was observed and comparable with
similar studies on other radiolabelled RGD peptides [14, 22,
24]. In general, our biodistribution data is in line with the
biodistribution data in healthy subjects, reported by Lopez
et al. [21]
The large variation in the observed SUV uptake values is
most likely the reflection of differences in αvβ3 integrin ex-
pression patterns. On the other hand, it may reflect a combi-
nation of radiotracer binding to neovasculature or tumour
cells. In previous studies, it was reported that HNSCCs ex-
press αvβ3 integrins solely on the neovasculature of tumours
[10, 23], while other solid tumours, e.g. renal cell carcinomas,
also demonstrated αvβ3 integrin expression on the tumour
cells themselves [25, 26]. The current study identified addi-
tional staining of tumour cells in two tumours with highly
keratinizing OSCC phenotype which did not result in higher
SUV values. Although this could be nonspecific, this might
also indicate that histological subtypes of cancer have distinct
expression patterns of αvβ3 integrin. Similar findings were
Fig. 4 PET/CT after injection of 218 MBq 68Ga-RGD in a patient with a
moderately differentiated SCC in the right oral cavity. a Transverse plane
of magnetic resonance image. b Fused PET/CT of the oral cavity
revealing a tumour lesion with SUVmax of 6.5. c and d Sagittal and axial
PET images demonstrating a clearly visualised tumour in the oral cavity
Fig. 3 Microscopic images of consecutive tumour sections (×
20objective) stained with haematoxylin and eosin (a), anti-αvβ3
integrin (b) and double stained for CD34 (red), Ki-67 (green), and
DAPI (blue) (c). A heterogeneous expression pattern of αvβ3 integrin
expressing blood vessels at the tumour invasive front (T) is observed,
with both positive en negative stained endothelial cells (green en yellow
arrow, resp.)
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also reported by Beer et al. [23] Furthermore, the PET/CT
findings may reflect 68Ga-RGD binding to other subtypes of
integrins (e.g. α5β1 or αvβ5), which have showed its overex-
pression in several types of HNSCC [27]. RGD-based pep-
tides may bind other integrins, although with a lower affinity,
unlikely to have a significant effect on the quantification of
binding to αvβ3 integrins [11, 28] . Conversely,
neovasculature is not only a hallmark of cancer, it is also
essential in the process of (chronic) inflammatory processes
[29]. These αvβ3 integrin expression patterns could potential-
ly interfere with the interpretation of the RGD PET/CT find-
ings of the tumour neovasculature in and surrounding the tu-
mour microenvironment. Further investigation in the expres-
sion pattern of αvβ3 integrin and whether RGD PET/CT is a
valid measure of endothelial cell activation in tumours might
be relevant, especially in those molecular imaging studies
aiming to determine changes in angiogenesis during treatment
using RGD PET/CT.
While all primary tumours could be identified on 68Ga-
RGD PET/CT, not all lymph node metastases were identified.
Small lesions may be difficult to detect due to the limited
spatial resolution of PET/CT. On the other hand, the detection
rate may be limited due to low αvβ3 integrin expression pat-
terns in metastatic lesions as compared with primary tumour
tissue. RGD uptake tends to be higher in those lymph nodes
with large metastases than those without confirmed metastatic
disease or smaller lymph nodemetastases (< 5 mm). Although
to lesser extent than in tumours, αvβ3 integrins are also
expressed during inflammation, e.g. on endothelial cells and
activated macrophages, which might in part explain uptake in
reactive lymph nodes that drain the primary tumour area.
A limitation of this study is the small number of patients
with OSCC included, which does not fully reflect the hetero-
geneity of HNSCC, with its many different biological charac-
teristics. Microenvironmental differences and their effect on
68Ga-RGD PET/CT need to be elucidated in further studies
and may allow more detailed analysis of the variability in
SUV values and integrin αvβ3 expression pattern across the
patients. The 68Ga-RGD PET/CT findings may be of interest
to differentiate between HNSCC subtypes and may allow
stratification of those patients who will most likely respond
to conventional treatment or treatment with angiogenic inhib-
itors [27]. Previously, a preclinical and clinical pilot study
have demonstrated the feasibility of treatment response mon-
itoring in HNSCC xenografts and patients using RGD PET/
CT [30, 31], but it is required to study this in prospective
clinical trials with more patients.
In conclusion, the results of this study support the feasibil-
ity of 68Ga-RGD PET/CTas a molecular imaging technique of
αvβ3 integrin expression in OSCC. It is a potential candidate
to evaluate tumour angiogenesis during treatment and may
also provide more insight in the vasculature of the distinct
tumour microenvironments of HNSCC.
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